It is the cache of ${baseHref}. It is a snapshot of the page. The current page could have changed in the meantime.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.

Smoking cessation therapy with varenicline
skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

14804

Smoking cessation therapy with varenicline



Review

(4783) Total Article Views


Authors: Uma M Mohanasundaram, Rajinder Chitkara, Ganesh Krishna

Published Date June 2008 Volume 2008:3(2) Pages 239 - 251
DOI: http://dx.doi.org/10.2147/COPD.S1848

Uma M Mohanasundaram, Rajinder Chitkara, Ganesh Krishna

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, CA, USA

Abstract: Smoking cessation is the only available intervention proven to halt progression of chronic obstructive pulmonary disease (COPD). The authors discuss the current existing treatment modalities and the role of a newly approved agent, varenicline, in promotion of smoking cessation. Varenicline is a novel agent that is a centrally acting partial nicotinic acetylcholine receptor agonist. It has both agonistic and antagonistic properties that together are believed to account for reduction of craving and withdrawal as well as blocking the rewarding effects of smoking. Its targeted mechanism of action, better efficacy and tolerability makes varenicline a useful therapeutic option for smoking cessation. In this article, we discuss presently available options for smoking cessation and review the literature on efficacy of varenicline.

Keywords: smoking cessation, varenicline, nicotine, receptors, therapy, COPD




Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter


Readers of this article also read:
  • Journal Indexing

    See where all the Dove Press journals are indexed.

  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, University of Texas Health Science Center, San Antonio.